Latest findings have put Hunter Firm under close review concerning its drug development and promotion methods. Concerns regarding seemingly questionable testing protocols and pushy promotion approaches have ignited extensive unease among officials, stakeholders, and patient advocacy groups. The situation is prompting a thorough assessment and coul